Cell therapy industry: Billion dollar global business with unlimited potential

Regenerative Medicine

Volumn 6, Issue 3, 2011, Pages 265-272

  Mason, Chris ^a   Brindley, David A ^a   Culme Seymour, Emily J ^b,c   Davie, Natasha L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Future Medicine Ltd   (United Kingdom)

^c London Regenerative Medicine Network   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CELL THERAPY; ENTERITIS; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE INDUSTRY; HEALTH CARE SYSTEM; HEALTH SERVICE; MEDICAL RESEARCH; MEDICARE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REGENERATIVE MEDICINE; REIMBURSEMENT; REVIEW; STEM CELL TRANSPLANTATION;

BIOTECHNOLOGY; EQUIPMENT AND SUPPLIES; INTERNATIONALITY; MARKETING OF HEALTH SERVICES; TISSUE THERAPY;

EID: 79955797571     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.11.28     Document Type: Review

References (37)

1. Mason C, Dunnill P: A brief definition of regenerative medicine. Regen. Med. 3(1), 1-5 (2008). (Pubitemid 351541190)
2. Mason C, Manzotti E: Regen: the industry responsible for cell-based therapies. Regen. Med. 4(6), 783-785 (2009).
3. Lysaght MJ, Crager J: Origins. Tissue Eng. Part A 15(7), 1449-1450 (2009).
4. Mason C: Regenerative medicine 2.0. Regen. Med. 2(1), 11-18 (2007). (Pubitemid 46824409)
5. Mason C: Regenerative medicine. The industry comes of age. Med. Device Technol. 18(2), 25-30 (2007).
6. Helble M: The movement of patients across borders: challenges and opportunities for public health. Bull. World Health Organ. 89(1), 68-72 (2011).
7. Carrera PM, Bridges JF: Globalization and healthcare: understanding health and medical tourism. Expert Rev. Pharmacoecon. Outcomes Res. 6(4), 447-454 (2006). (Pubitemid 44304753)
8. Mason C, Manzotti E: Defeating stem cell tourism. Regen. Med. 5(5), 681-686 (2010).
9. Mason C, Dunnill P: The need for a regen industry voice. Regen. Med. 3(5), 621-631 (2008).
10. Fox LJ: Relief over stem cell lines. Nat. Biotechnol. 28, 538 (2010).
11. Daar AS, Nabel EG, Pramming SK et al.: The global alliance for chronic diseases. Science 324(5935), 1642 (2009).
12. Christensen CM: The Innovators Dilemma. Harper Business, NY, USA (2000).
13. Ellis H: James Blundell, pioneer of blood transfusion. Br. J. Hosp. Med. (Lond.) 68(8), 447 (2007).
14. Daniels JT, Notara M, Shortt AJ, Secker G, Harris A, Tuft SJ: Limbal epithelial stem cell therapy. Expert Opin. Biol. Ther. 7(1), 1-3 (2007). (Pubitemid 46089205)
15. Evers P: Advances in the Stem Cell Industry. Global Business Insights (2009).
16. Mason C, Manzotti E: Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med. 5(3), 307-313 (2010).
17. Lichtenberg FR: Despite steep costs, payments for new cancer drugs make economic sense. Nat. Med. 17(3), 244 (2011).
18. Mason C, Manzotti E: The translation cycle: round and round in cycles is the only way forward for regenerative medicine. Regen. Med. 5(2), 153-155 (2010).
19. Irv Weissman. Nat. Biotechnol. 29(3), 194 (2011).
20. Tan PL: Company profile: tissue regeneration for diabetes and neurological diseases at Living Cell Technologies. Regen. Med. 5(2), 181-187 (2010).
21. McKernan R: An audience with Ruth McKernan. Nat. Rev. Drug Discov. 8(3), 188 (2009).
22. McKernan R, McNeish J, Smith D: Pharmas developing interest in stem cells. Cell Stem Cell 6(6), 517-520 (2010).
23. Van Bokkelen G: Company profile: Athersys. Regen. Med. 6(1), 39-43 (2011).
24. Allison M: Genzyme backs Osiris, despite Prochymal flop. Nat. Biotechnol. 27(11), 966-967 (2009).
25. Cephalon splashes out on mesenchymal stem cells. Nat. Biotechnol. 29(2), 97 (2011).
26. Aggarwal S: Whats fueling the biotech engine -2009-2010. Nat. Biotechnol. 28(11), 1165-1171 (2010).
27. House of Commons, Bioengineering -Science and Technology Committee Contents: Memorandum submitted by Professor Chris Mason (Bio 31) www.parliament.the-stationery-office.co.uk/pa/cm200910/cmselect/cmsctech/220/ 10010606.htm
28. Alliance for Regenerative Medicine: Membership www.alliancerm.org/ members.html
29. Biotechnology Industry Organisation: About BIO: Partner to a dynamic industry coming of age www.bio.org/aboutbio/history.asp
30. Bloomberg Businessweek. Dendreons Provenge extends survival, U.S. Panel says Larkin C www.businessweek.com/news/2010-2011-17/dendreon-s-provenge- extends-survival-u-s-panel-says.html
31. Larkin C, Waters R: Bloomberg Dendreon says Provenge may generate $400 million, reports expansion plans www.bloomberg.com/news/2011-2001- 07/dendreon-reports-projected-provenge-sales-of-400-million-expansion-plans.html
32. Medical News Today: Osiris receives FDA clearance to broaden prochymal expanded access program www.medicalnewstoday.com/articles/135938.php
33. Biotechnology Industry Organisation: New study shows the rate of drug approvals lower than previously reported www.bio.org/news/pressreleases/ newsitem. asp?id=2011-0214-02
34. United States Securities and Exchange Commission (Washington, DC): February 25, 2011. Registration Number 333 -Form S-1 Registration Statement under the Securities Act 1993 -Advanced BioHealing Inc. http://ipo.nasdaq.com/ ViewFiling-frames.asp?filename=0001193125%2D11%2D046975%2Etxt&filepath= %5C2011%5C02%5C25%5C
35. Dendreon Corporation United States Securities and Exchange Commission (Washington, DC): Form 10-K Annual Report Fiscal year ended 31 December 2010 http://files.shareholder.com/downloads/DNDN/1169714058x0xS950123%2D11%2D20518/ 1107332/filing.pdf
36. Fibrocell Science: Press release March 16th 2011 -Fibrocell Science, Inc. submits final data from histology study to FDA www.fibrocellscience.com/media/ 2011/2011-03-16.htm
37. UK Treasury and Department of Business Innovation and Skills: The plan for growth (page 94) www.hm-treasury.gov.uk/ukecon-growth-index.htm